Boston Partners Trims Holdings in Smith & Nephew SNATS, Inc. $SNN

Boston Partners trimmed its position in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 16.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 109,018 shares of the medical equipment provider’s stock after selling 20,875 shares during the quarter. Boston Partners’ holdings in Smith & Nephew SNATS were worth $3,339,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. AlphaCore Capital LLC acquired a new position in shares of Smith & Nephew SNATS in the 2nd quarter worth approximately $44,000. Banque Transatlantique SA acquired a new stake in shares of Smith & Nephew SNATS during the first quarter worth about $52,000. Bessemer Group Inc. grew its stake in shares of Smith & Nephew SNATS by 111.9% in the second quarter. Bessemer Group Inc. now owns 3,709 shares of the medical equipment provider’s stock worth $114,000 after acquiring an additional 1,959 shares in the last quarter. Geneos Wealth Management Inc. raised its position in Smith & Nephew SNATS by 15.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 4,149 shares of the medical equipment provider’s stock valued at $118,000 after purchasing an additional 541 shares in the last quarter. Finally, Brooklyn Investment Group lifted its stake in Smith & Nephew SNATS by 3,086.3% in the first quarter. Brooklyn Investment Group now owns 4,429 shares of the medical equipment provider’s stock worth $126,000 after acquiring an additional 4,290 shares during the last quarter. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Stock Performance

SNN stock opened at $33.28 on Friday. The stock has a 50-day moving average price of $35.05 and a two-hundred day moving average price of $33.38. Smith & Nephew SNATS, Inc. has a 12-month low of $23.69 and a 12-month high of $38.79. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40.

Analyst Ratings Changes

A number of equities analysts recently issued reports on SNN shares. Canaccord Genuity Group lowered their price target on Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating for the company in a report on Tuesday, November 11th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Smith & Nephew SNATS in a research report on Monday, October 20th. Wall Street Zen downgraded Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Friday, October 3rd. Sanford C. Bernstein set a $37.50 price target on shares of Smith & Nephew SNATS and gave the company a “market perform” rating in a research report on Tuesday, October 14th. Finally, Kepler Capital Markets upgraded shares of Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday, November 17th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $35.75.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.